Lightbits Labs Named Storage Company of the Year and Receives Storage Hardware Award for SuperSSD NVMe/TCP at SDC Awards
3.12.2019 16:00:00 EET | Business Wire | Press release
At the recent SDC Awards gala here, Lightbits Labs took home two prestigious awards, Storage Company of the Year and Hardware Innovation of the Year. Lightbits received the nod for storage company of the year for its software defined storage (SDS) solution that brings hyperscale efficiency to on-premise cloud infrastructure with low-latency composable storage. Lightbits’ SuperSSD NVMe/TCP Storage Server , the World’s First Ultra-High Capacity, High Performance SSD Storage Appliance solution was selected as the most innovative hardware solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203005290/en/
Lightbits Labs takes home storage company of the year and wins storage hardware award for SuperSSD NVMe/TCP at the SDC Awards. Posing with the awards from left to right are: Kam Eshghi, Chief Strategy Officer, Shirley Kirzner, Eran Kirzner, Chief Executive Officer and Co-Founder, George Agasandian, Director of Solutions Engineering and Co-Founder, Ofir Efrati, VP of Engineering and Co-Founder, Shaul Galia, Chief Operations Officer, and Miki Avni, Chief Financial Officer. (Photo; Business Wire)
The SDC (Storage, Digitalization + Cloud) Awards, now in their 10th year, recognize and reward success in the products and services that are foundational to digital transformation. Lightbits received the honor for how the company is reimagining hyperscale storage for next-generation applications.
Co-founded by veteran Israeli entrepreneur and founder of Annapurna Avigdor Willenz, Lightbits introduced three groundbreaking technologies in its first year out of stealth mode: LightOS, LightField, and SuperSSD. The company was cited for its leadership in delivering software defined solution that runs on commodity hardware to disaggregate storage and compute over standard networks, allowing them to scale independently (increasing flexibility & efficiency) and maximizing resource utilization (lowering TCO) while delivering performance that is similar to direct-attached SSDs. Lightbits pioneered NVMe/TCP so its solution is easy to deploy at scale.
“Being recognized by our peers and voters from around the globe for this award highlights the increasingly important role of practical, smart and forward-thinking storage solutions for true digital transformation,” said Eran Kirzner, co-founder and CEO at Lightbits Labs. “Companies are responsible for vast amounts of data through both public and private clouds, and the volume of data continues to grow exponentially. We’re proud that our solutions are being recognized for their transformational role in addressing the data storage challenges that are so prevalent in enterprises today.”
In March 2019, Lightbits introduced its groundbreaking LightOS and LightField. The LightOS software and LightField storage acceleration card provide a high-performance, end-to-end disaggregation solution that can scale without requiring any changes to data center clients or network infrastructure. They were the industry’s first NVMe/TCP solutions to provide a Global Flash Translation Layer (GFTL) running over high-performance standard networks. The solutions allow private clouds and software-as-a-service (SaaS) providers to capitalize on the application performance of using local NVMe SSDs with the simplicity and efficiency of hyperscale solutions.
As trailblazers of a new storage paradigm, Lightbits’ solutions are successfully being used in industry-leading cloud data centers around the globe. The company is gaining industry recognition for its ground-breaking solutions and has received three industry awards over the past six months.
Lightbits Labs Resources
For additional information, contact info@lightibtslabs.com
About Lightbits Labs™
Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz, Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht, (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005290/en/
Contact information
Alan Ryan/Marianne Dempsey
alanryan@rainierco.com/ mdempsey@rainierco.com
508-475-0025, ext. 116 or 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom